Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Market Cap	14.12B +231.0%
Revenue (ttm)	1.01B +12.8%
Net Income	319.00M +38.1%
EPS	34.25 +38.1%
Shares Out	9.31M
PE Ratio	44.26
Forward PE	n/a
Dividend	6.00 (0.39%)
Ex-Dividend Date	Mar 30, 2026

Volume	241,700
Average Volume	595,000
Open	1,542.00
Previous Close	1,542.00
Day's Range	1,506.00 - 1,560.00
52-Week Range	356.00 - 3,820.00
Beta	-0.28
RSI	46.61
Earnings Date	Feb 12, 2026

About TYO:4570

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer’s disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtrat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1982
• Employees: 58
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4570

Financial Performance

In fiscal year 2025, TYO:4570's revenue was 969.00 million, an increase of 18.75% compared to the previous year's 816.00 million. Earnings were 249.00 million, an increase of 33.87%.